... presented in a poster at the San Antonio Breast Cancer Symposium 2022. ... Disclosures: Some study authors declared affiliations with biotech, ...
News
- DFS Improved With AIs vs Tamoxifen in HR+, HER2- Early Breast Cancer
- Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines ... - BioSpace
DAN-222 Phase 1 dose-escalation data at San Antonio Breast Cancer Symposium ... Dantari, Inc. is a clinical-stage biotechnology company developing ...
- Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset ...
... One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS) ...
- Dantari emerges with a new way to make cancer drug conjugates - BioPharma Dive
Dive Brief // Emerging biotech ... set to be presented Thursday at the San Antonio Breast Cancer Symposium, ... STORYLINE // Emerging biotech.
- Longer follow-up supports benefit of abemaciclib for high-risk breast cancer - Healio
SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time ...